Clinical Trial

A Study of Buntanetap in Participants With PD

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2025-12-09; most recent amendment 2026-07-20.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT07284784
Lead Sponsor Annovis Bio Inc.
Collaborators: Duke Clinical Research Institute
Conditions Parkinson's Disease (PD), Deep Brain Stimulation
Enrollment 500 participants
Start Date 2026-01-09
Primary Completion 2029-09 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-21